AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
132 hedge funds and large institutions have $1.1B invested in Aimmune Therapeutics in 2018 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 37 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
10% less capital invested
Capital invested by funds: $1.21B → $1.1B (-$115M)
30% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 33
Holders
132
Holding in Top 10
4
Calls
$4.9M
Puts
$1.98M
Top Buyers
| 1 | +$19.1M | |
| 2 | +$9.57M | |
| 3 | +$9.14M | |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$6.1M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$5.75M |
Top Sellers
| 1 | -$15.1M | |
| 2 | -$7.94M | |
| 3 | -$6.45M | |
| 4 |
BlackRock
New York
|
-$6.21M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.11M |